Total Reports
65
Below-median volume
Breed profile · FDA CVM July 2026 extract
Adverse-event filings for Brangus (Cattle) in the FDA Center for Veterinary Medicine openFDA extract. Browse cattle breeds, reactions, and outcomes below.
By recorded gender -- every report on file for Brangus, no filtering.
Data updated September 2026
The verdict
According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Brangus ranks #255 of 510 by total reports (65) and #14 of 275 by death-coded share (43.1%). National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).
Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.
Release-over-release change
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Brangus has 65 reports now versus 65 in that prior snapshot: 0 the same number of (0.0%).
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Brangus changesTotal Reports
65
Below-median volume
Deaths Reported
28
of 65 reports
Death-coded share of reports
43.1%
Highest death-coded share
Avg Age at Report
1.9 yr
237.9 kg avg weight
43.1% of 65 brangus reports involved a death outcome.
Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
| Year | Reports | Trend |
|---|---|---|
| 2010 | 10 | |
| 2011 | 1 | |
| 2012 | 3 | |
| 2013 | 3 | |
| 2014 | 3 | |
| 2015 | 8 | |
| 2016 | 2 | |
| 2017 | 7 | |
| 2018 | 6 | |
| 2019 | 3 | |
| 2020 | 3 | |
| 2021 | 3 | |
| 2022 | 3 | |
| 2023 | 4 | |
| 2024 | 3 | |
| 2025 | 3 | |
Signature read: Brangus's 43.1% death-coded share is in the upper third of the ≥50-report cohort (median 4.8%). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Brangus sits at #256 of 510 by report volume among all breeds and #13 of 30 among cattle breeds, with 65 reports and 28 (43.1%) death-coded. On death-coded share among breeds with ≥50 reports, it ranks #14 of 275. Mean age at report: 1.9 years, average weight 237.9 kg (524.6 lbs).
Top reported signs: Death (23), Lack of efficacy - NOS (10), Lack of efficacy (bacteria) - NOS (6). Most-referenced drug: Eprinomectin 5% Injection (8 reports), followed by Doramectin (6) and Moxidectin (6).
Outcome coding on 68 status-recorded reports is dominated by Died (38.2%). Annual submissions ranged 1-2,025 across 16 years on file.
Showing 6 of 29 cattle breeds in our dataset, ranked by closest report volume.
Two openFDA-derived peer sets for Brangus, both outside the Cattle family so the neighborhoods are not species containment (the similar-volume list above stays within species).
Nearest other-species breeds with ≥50 reports (43.1% death-coded here).
Nearest other-species breeds by reported average weight (237.9 kg here).
What to do with this cattle
A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.
Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →